Tagrisso has been approved in the United States for adjuvant treatment of adults patients diagnosed early enough for the tumor to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said.
AstraZeneca's Tagrisso gets broader US approval for lung cancer
By REUTERS
11/05/2024 01:17 AM
By REUTERS
11/05/2024 01:02 AM
By REUTERS
11/04/2024 10:04 PM
By REUTERS
11/04/2024 10:01 PM
By REUTERS
11/04/2024 09:51 PM
By REUTERS
11/04/2024 08:38 PM
By REUTERS
11/04/2024 07:15 PM